Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome
NCT ID: NCT00127881
Last Updated: 2012-07-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
76 participants
INTERVENTIONAL
2005-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Zanolimumab
HuMax-CD4 (zanolimumab)
Monoclonal Antibody, 12 weekly infusions.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HuMax-CD4 (zanolimumab)
Monoclonal Antibody, 12 weekly infusions.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Refractory to or intolerant to at least two prior therapies, one being Targretin® (or combinations hereof).
* Signed informed consent
Exclusion Criteria
* Prior treatment with Campath (alemtuzumab)
* Prior treatment with more than three regimens of single agent chemotherapy
* Prior treatment with pentostatin within 6 months
* Treatment within 4 weeks prior to visit 2 with topical Targretin®, skin directed therapies or systemic anticancer therapies, such as, but not limited to: Targretin® , UV-light therapy, local Electron Beam Therapy (EBT), extracorporal photo chemotherapy, methotrexate, bleomycin, cyclophosphamide, combination chemotherapy, oral retinoids, systemic glucocorticosteroids , carmustine, nitrogen mustard, systemic vitamin A or etretinate
* Treatment with topical glucocorticosteroids within 2 weeks prior to visit 2
* Unwillingness or inability to avoid prolonged exposure to the sun or UV light sufficient to produce a mild erythema or thought by the investigator to likely modify the patient's disease
* Concurrent or previous malignancies within the past five years except adequately treated in situ carcinoma of the uterine cervix or basal or squamous cell skin carcinoma
* Significant concurrent, uncontrolled, or active medical condition including, but not limited to renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, cerebral or psychiatric disease
* Known or suspected positive serology for HIV
* Known or suspected positive serology for hepatitis B or C
* Patients who are currently participating in any other trials or having received treatment with any experimental agent within 4 weeks prior to visit 1 (screening)
* Prior treatment with anti-CD4 monoclonal antibodies
* Breast feeding women or women with a positive pregnancy test at Visit 1
* Women of childbearing potential not willing to use either hormonal birth control, an intrauterine device or double-barrier method for the entire study period
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Emergent Product Development Seattle LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
Stanford University Medical Center
Stanford, California, United States
University of Colorado
Aurora, Colorado, United States
H. Lee Moffitt Cancer Center
Tampa, Florida, United States
The Emory Clinic
Atlanta, Georgia, United States
Northwestern University
Chicago, Illinois, United States
Tulane University Health Science Center
New Orleans, Louisiana, United States
Boston Medical Center
Boston, Massachusetts, United States
University of Michigan Medical Center
Ann Arbor, Michigan, United States
New York Medical Center
New York, New York, United States
Memorial Sloan Kettering
New York, New York, United States
SUNY Upstate Medical University
Syracuse, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
University Hospital of Cleveland
Cleveland, Ohio, United States
Ohio State University
Columbus, Ohio, United States
Oregon Health & Science University
Portland, Oregon, United States
University of Pennsylvania Health System
Philadelphia, Pennsylvania, United States
Middle Tennessee Research Institute
Nashville, Tennessee, United States
MD Anderson Cancer Center
Houston, Texas, United States
Hopital de I'Hotel-Dieu
Lyon, , France
Consultation Dermatologie Niveau moins 1 Hopital Archet 2
Nice, , France
Hopital Saint-Louis Service de Dermatologie
Paris, , France
Centre Hospitalier Lyon Sud Bat. 1F 1er etage service Hematologie
Pierre-Bénite, , France
Skin Cancer Center Charite Mitte Dermatologie Fran Ramona Kursawa
Berlin, , Germany
University of Essen - Universitatsklinikum Essen z. Hd. Frau Desire Zieling
Essen, , Germany
University of kiel, Klinik Fur Dermotologie, Christian-Albrechts-Universitat Zu
Kiel, , Germany
Klinikum Minden / Hautklinik Minden
Minden, , Germany
University of Wurzburg - Universitatsklinikum Wurzburg dermato-onkologische studien
Würzburg, , Germany
Instituto di Ematologia e Oncologia Medica "L. & A. Seragnoli"
Bologna, , Italy
Day Hospital Oncologico-Presidio Ospedaliero Firenze Centro Ospedale Santa Maria Nuova Azienda Sanitaria di Firenze, University of Florence
Florence, , Italy
University of Milan-Fondazione IRCCS di Natura Pubblica Ospedale Maggiore Policlinico Mangiagalli e Regina Elena di Milano via Francesco Sforza
Milan, , Italy
Instituto Dermopatico dell'Immacolata IRCCS via Monti di Creta
Roma, , Italy
University of Turin SCDU Dermosifilopatia 2 A.S.O. Molinette S.Giovanni Battista
Turin, , Italy
Hospital Universitario de la Princesa
Madrid, , Spain
Maternidad Planta Baja, Hospital 12 de Octubre
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Hx-CD4-110
Identifier Type: -
Identifier Source: org_study_id